- Home
- EYE vs NRIX Comparison
EYE vs NRIX Comparison
Compare EYE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYE | NRIX |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EYE | NRIX |
|---|---|---|
| Price | $23.00 | $16.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $31.22 | $30.50 |
| AVG Volume (30 Days) | ★ 1.2M | 820.0K |
| Earning Date | 05-13-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 202.78 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,987,488,000.00 | $76,987,000.00 |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $6.58 | $48.05 |
| P/E Ratio | $61.92 | ★ N/A |
| Revenue Growth | 9.00 | ★ 99.31 |
| 52 Week Low | $17.99 | $8.20 |
| 52 Week High | $30.02 | $22.50 |
Technical Indicators
Market Signals| Indicator | EYE | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 50.24 |
| Support Level | $22.15 | $16.02 |
| Resistance Level | $29.56 | $16.71 |
| Average True Range (ATR) | 1.23 | 0.76 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 28.74 | 36.24 |
Price Performance
Historical ComparisonAbout EYE National Vision Holdings Inc.
National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.